Meet the EAB: Aaron F. Bartlone
Get to know the newest ACT Editorial Advisory Board member.
Aaron F. Bartlone, MS, is vice president, preclinical and clinical quality assurance at UCB Pharma, Smyrna, GA. In this role, he leads a global organization of quality professionals based in the United States, Europe, and Japan. Aaron partners with UCB's Development and Medical Affairs organizations to establish robust Quality Systems that ensure GXP compliance while streamlining business processes and maximizing efficiencies. In addition, Aaron's organization executes field surveillance for safety and efficacy studies to ensure trial subjects' safety and rights are protected and that data generated from these studies are accurate and reproducible.
Aaron F. Bartlone, MS, vice president, preclinical and clinical quality assurance, UCB Pharma
Prior to joining UCB, Aaron was head of quality operations-product research & development, with Eli Lilly & Company, Indianapolis, IN, responsible for developing the strategy and framework for Lilly's product research & development quality system.
Aaron's earlier positions with Eli Lilly include European quality director-global product development in Mont-Saint Guibert, Belgium (2001–2004), where he led the delivery of quality assurance services across European drug development sites. Aaron had a staff of quality professionals located in Belgium and Germany, and worked closely with his U.S. counterparts to institute global processes and quality systems commensurate with international regulations and industry-best practices.
Prior to working at Lilly's Mont-Saint Guibert, Belgium, location, Aaron held numerous positions with Lilly in Indianapolis, IN: quality control manager-global product development (1999–2001); head of quality-biotechnology quality control and quality control laboratories (1998–1999); quality control team leader-oral and parenteral clinical products (1997–1998); senior compliance auditor-corporate quality assurance (1996–1997); and laboratory group leader-quality control laboratories (1994–1996).
From 1992 to 1995, Aaron was an associate professor at Ivy Tech State College, Indianapolis, IN, where he taught chemistry, physics, and mathematics, and participated in the design of a new laboratory teaching facility. Earlier, he was a clinical toxicologist with South Bend Medical Foundation, South Bend, IN, performing laboratory procedures for substances of abuse and forensic investigations.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
